Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | NAMPT | P43490 | 3/20 | 0.58 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294670 | 1.00 | RAB9A (0.61) | RAB9ANPC1PKMEPHX2HTT | |
| SCHEMBL17294672 | 1.00 | RAB9A (0.61) | RAB9ANPC1PKMEPHX2HTT | |
| SCHEMBL5004386 | 0.83 | ROCK2 (0.64) | RAB9ANPC1PKMEPHX2HTT | |
| SCHEMBL29521360 | 0.83 | POLB (0.68) | RAB9ANPC1EPHX2HTTLMNA | |
| SCHEMBL19954280 | 0.83 | POLB (0.68) | RAB9ANPC1EPHX2HTTLMNA | |
| SCHEMBL29521435 | 0.82 | LMNA (0.63) | HTTLMNA | |
| SCHEMBL6345670 | 0.80 | RAB9A (0.52) | RAB9ANPC1PKMEPHX2HTT | |
| SCHEMBL5104098 | 0.80 | HTT (0.72) | RAB9ANPC1EPHX2HTTLMNA | |
| SCHEMBL11588542 | 0.79 | POLB (0.62) | HTTLMNAALDH1A1L3MBTL1GAA | |
| SCHEMBL4529522 | 0.77 | ROCK2 (0.58) | HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | claimed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | claimed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | claimed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | claimed |
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-01 | — | — | US | disclosed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022065962-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | 한국화학연구원 | 2022-03-31 | — | — | WO | disclosed |
| CN-106659697-B | Compounds as antituberculosis agents | 斯菲叶尔制药私有公司 | 2022-03-29 | — | — | CN | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | disclosed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | MLKL, PCSK9, CTSA | RAB9A 2369/4885NPC1 187/4885PKM 911/4885 |
| US-10207993-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | RAB9A 883/4885NPC1 38/4885PKM 2214/4885 |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | RAB9A 704/4885NPC1 33/4885PKM 2411/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | RAB9A 704/4885NPC1 33/4885PKM 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.